Understanding how bile acid transporter inhibitors protect the liver and kidneys.
Official title: Hepatoprotective Mechanisms of Systemic Bile Acid Transporter Inhibitors
Funded at Emory University · NIH-10943543 · Data updated 2026-11-12
This study is looking at how a certain bile acid transporter affects liver and kidney problems caused by bile buildup, and it aims to see if blocking this transporter can help protect these organs, which could be helpful for people dealing with cholestatic liver diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $639,190 |
| NIH project number | 1R01DK140485-01 |
| Project ID | NIH-10943543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with cholestatic liver diseases, such as Alagille Syndrome or bile duct obstruction.
✕Less likely to help
Patients with liver diseases not related to cholestasis or those without kidney involvement may not benefit from this research.
What this research studies
This research investigates the role of a specific bile acid transporter in liver diseases that cause bile accumulation and kidney injury. It aims to understand how inhibitors of this transporter can help protect the liver and kidneys from damage. The study will utilize advanced imaging techniques and genetic models to explore the effects of these inhibitors on both liver and kidney function. By focusing on the mechanisms involved, the research seeks to identify potential therapeutic benefits for patients suffering from cholestatic liver diseases.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect the liver and kidneys in patients with cholestatic liver diseases.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting bile acid transporters in liver diseases.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Dawson, Paul a — Emory University
- Study coordinator: Dawson, Paul a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.